Iconic Therapeutics to Present Phase 2a EMERGE Trial Results at Miami Meeting

SOUTH SAN FRANCISCO, Calif.--()--Iconic Therapeutics, a clinical stage biopharmaceutical company dedicated to translating knowledge of Tissue Factor biology into new therapeutics for retinal disease and cancer, announced today that the results of its recently completed EMERGE trial, a Phase 2a randomized, double-masked, multi-dose study of the drug candidate ICON-1 in wet Age-Related Macular Degeneration (AMD), will be presented for the first time at the Angiogenesis, Exudation, and Degeneration meeting in Miami, FL on Saturday February 11. The trial design included assessment of outcomes specifically designed to measure lesion growth and leakage, both hallmarks of disease progression in AMD. The EMERGE trial was a six-month, active-controlled, multi-center study of 88 patients with newly diagnosed disease. Iconic previously completed an 18-subject Phase 1 clinical trial in neovascular AMD, which demonstrated safety and preliminary evidence of potential biologic activity.

“The EMERGE data point to ICON-1’s potential to directly address the limitations of currently approved therapies. While the study was not powered for statistical significance, we saw strong signals of biologic activity that provide a clear rationale for further clinical development. We expect to initiate further studies later this year.”

According to William Greene, M.D., Chief Executive Officer, “The EMERGE data point to ICON-1’s potential to directly address the limitations of currently approved therapies. While the study was not powered for statistical significance, we saw strong signals of biologic activity that provide a clear rationale for further clinical development. We expect to initiate further studies later this year.”

About AMD

Age-related Macular Degeneration is the leading cause of blindness in the U.S. and other industrialized countries, affecting up to 200 million people worldwide. The ultimate goal of AMD treatment is to preserve vision and prevent blindness. For over a decade, anti-VEGF agents have been the standard of care, providing good initial responses with rapid reduction of retinal thickness and, in up to 40% of patients, gains in vision. However, treatment with anti-VEGF agents alone may not provide durable outcomes. For many patients, vision gains do not appear to be sustainable over a period of years and thus may not prevent progression to blindness in the long run. There is an unmet need for an agent that can modify the underlying progression of the disease process itself.

About Iconic Therapeutics

Iconic Therapeutics is a clinical stage biopharmaceutical company dedicated to translating an understanding of the role of Tissue Factor biology to new therapeutics for retinal disease and cancer. The company’s lead product candidate, ICON-1, is a novel fusion protein designed to address the basis of vision loss in AMD. By targeting inflammation and angiogenesis together, ICON-1 may potentially alter the course of this leading cause of blindness. The company is investigating the ICON family of proteins in cancer and has initiated a research program in solid tumors. Please visit www.iconictherapeutics.com for additional information.

Contacts

Annes Associates
Shari Annes, 650-888-0902
sannes@annesassociates.com

Recent Stories

RSS feed for Iconic Therapeutics